Biotech Startups

MOAB develops minibinders — small, stable, modular protein binders based on natural scaffolds — for use as new therapeutics. The company runs a data generation platform and AI models that design minibinder sequences by learning from biological function.

1 investor

Moberg Analytics develops the Moberg Clinical Platform (MCP), software that aggregates and analyzes high-resolution multimodal neuromonitoring data from disparate ICU devices into near real-time insights. It serves clinicians and researchers in neurocritical care, particularly the neuro ICU and severe TBI treatment.

1 investor

Mobius Scientific develops treatments for age-related macular degeneration and other retinal diseases by targeting the root cause of vision loss. The company serves patients with progressive vision loss globally.

1 investor

Mobius Therapeutics makes Mitosol, an FDA-indicated mitomycin kit used topically as an adjunct to ab externo glaucoma filtration surgery. The product is a prescription ophthalmic pharmaceutical for use by eye surgeons treating glaucoma.

1 investor

MOC Biotechnologies builds hybrid 4D bioprinters and biomechatronic systems that print hard and soft tissue, organs, and cell scaffolds using hydrogels, polymers, and drugs for preclinical drug discovery and regenerative medicine. It serves research centers, universities, laboratories, and preclinical CROs, with applications including cancer research.

1 investor

Modern Synthesis is a biotechnology company that uses bacteria to produce nanocellulose-based biomaterials, creating bio-based coated textiles as plastic- and petrochemical-free alternatives to materials like leather. It supplies these materials to fashion, automotive, and other brands and manufacturers, with production based in South West London.

1 investor

ModernVivo is a software platform that automates literature review and analysis for in vivo study design in pharmaceutical research and preclinical development. It serves pharmaceutical companies, contract research organizations, academic labs, and institutional animal care committees by extracting study parameters from scientific literature to accelerate drug discovery timelines.

1 investor

Modulate Bio develops small-molecule GABAA positive allosteric modulators to treat neurological disorders including Essential Tremor, epilepsy, and anxiety. Its drug-discovery platform aims to selectively activate specific GABAA receptor subunits to provide efficacy while limiting side effects.

1 investor

Modulation Therapeutics discovers and develops novel drug candidates targeting aggressive cancers and liver disease using peptide-based, small molecule, and targeted radio-therapy approaches. Founded in 2011 as a spinoff of Moffitt Cancer Center and now based in Morgantown, West Virginia, the company aims to advance three first-in-class therapies for nine disease indications through FDA approval.

1 investor

Modus is a Swedish biotechnology company developing sevuparin, a proprietary polysaccharide, as a treatment for conditions with high unmet medical need including sepsis and septic shock, severe systemic inflammation such as severe malaria, and anemia related to chronic inflammation like kidney disease.

1 investor

Mojiabio produces Aliphane, a bio-based chemical ingredient used in adhesives for applications including wood furniture, footwear, flexible packaging, automotive, and EV batteries.

1 investor

Molab.ai develops technology for small molecule drug discovery. It was acquired by Cresset, a provider of software for digitizing drug discovery.

1 investor

Molagri develops biopesticides that target harmful insects through specific molecular mechanisms while protecting beneficial insects and the environment, and incorporates resistance modeling to maintain product efficacy over time.

1 investor

MolCube develops software for molecular modeling and simulation targeting pharmaceutical, biotechnology, and nanotechnology companies. The products enable complex biological and nanomaterial system simulation and computer-aided drug discovery through web-based or locally-installed solutions.

1 investor

MOLECUBES develops benchtop preclinical imaging systems ("CUBES") for SPECT/CT and PET/CT studies, aimed at researchers working in limited laboratory space. The company serves the preclinical research market with a focus on user-friendly workflow, high throughput, and system uptime.

1 investor

Molecular Designs develops and sells research assays and molecular diagnostic panels designed to run on standard PCR platforms, serving research labs seeking cost-effective and efficient testing solutions. The company offers direct-to-customer purchasing with customization options and supply chain support.

1 investor

Molecular Devices provides automated systems and services to support 3D cell biology research workflows, including cell culture automation, organoid expansion services, and imaging analysis tools for drug discovery and preclinical research.

1 investor

Focused on Engineered Toxin Bodies immunotoxins for cancer treatment.

1 investor

MT develops cancer-specific molecular imaging agents (probes) targeting a common oncoprotein in the tumor microenvironment, intended for use with imaging modalities such as CT, PET, MRI, SPECT and ultrasound. The agents are aimed at early detection and diagnosis of aggressive tumors across multiple cancer types for clinical cancer management.

1 investor

Molecular Instruments develops HCR (hybridization chain reaction) imaging products for enzyme-free, multiplex, quantitative in situ hybridization and immunofluorescence, enabling detection of RNA and protein targets. Its products serve researchers in life sciences performing high-resolution imaging and expression profiling of cells and tissue samples.

1 investor

Moleculera Biosciences is a precision medicine company that develops blood-based immune-mediated autoantibody testing panels and AI-driven diagnostic tools to identify immune dysfunction underlying chronic neuropsychiatric and cardiovascular disorders, as well as Alzheimer's disease. The company operates an integrated platform combining diagnostic panels, a biorepository with bioinformatics, and a therapeutic target identification program.

1 investor

MolecuLynx builds browser-based software for chemical inventory management, safety compliance, and research collaboration, aimed at modern laboratories. Founded by chemists, the tools target researchers who need to organize lab operations and stay compliant.

1 investor

Molmir is an academic spinout developing technology to observe how molecules "move" and change shape based on liquid-liquid phase separation research, enabling previously undruggable dynamic molecules to be targeted in drug discovery. It focuses on diseases without established treatments such as ALS, Alzheimer's disease, cancer, and heart disease.

1 investor

MOLwise uses generative AI models, physics-based screening, and lab validation to design molecular recognition elements (aptamers and peptide binders) for biosensors. It takes a customer's target analyte — a protein, peptide, small molecule, or cell — and returns characterized binders, assay protocols, and integration notes for point-of-need biosensors.

1 investor